UBS Group’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.67M | Buy |
229,400
+5,717
| +3% | +$91.4K | ﹤0.01% | 3321 |
|
|
2025
Q1 | $3.4M | Buy |
223,683
+34,452
| +18% | +$524K | ﹤0.01% | 3285 |
|
|
2024
Q4 | $3.84M | Buy |
189,231
+177,385
| +1,497% | +$3.6M | ﹤0.01% | 3214 |
|
|
2024
Q3 | $305K | Buy |
11,846
+2,146
| +22% | +$55.2K | ﹤0.01% | 4400 |
|
|
2024
Q2 | $125K | Buy |
9,700
+6,879
| +244% | +$88.5K | ﹤0.01% | 4893 |
|
|
2024
Q1 | $64.6K | Buy |
+2,821
| New | +$64.6K | ﹤0.01% | 5239 |
|
|
2023
Q4 | – | Sell |
-14
| Closed | -$391 | – | 8558 |
|
|
2023
Q3 | $391 | Buy |
+14
| New | +$391 | ﹤0.01% | 7376 |
|
|
2023
Q2 | – | Sell |
-778
| Closed | -$14.6K | – | 8423 |
|
|
2023
Q1 | $14.6K | Sell |
778
-331
| -30% | -$6.22K | ﹤0.01% | 6242 |
|
|
2022
Q4 | $11.3K | Buy |
+1,109
| New | +$11.3K | ﹤0.01% | 7218 |
|
|
2022
Q3 | – | Sell |
-83
| Closed | -$4K | – | 9696 |
|
|
2022
Q2 | $4K | Buy |
+83
| New | +$4K | ﹤0.01% | 8096 |
|
|
2022
Q1 | – | Sell |
-811
| Closed | -$124K | – | 9622 |
|
|
2021
Q4 | $124K | Buy |
811
+76
| +10% | +$11.6K | ﹤0.01% | 5048 |
|
|
2021
Q3 | $100K | Buy |
735
+166
| +29% | +$22.6K | ﹤0.01% | 4757 |
|
|
2021
Q2 | $84K | Buy |
+569
| New | +$84K | ﹤0.01% | 4975 |
|